Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer

详细信息    查看全文

• 作者：Sungjae Baek¹ ; ^{haku@radonc.med.osaka-u.ac.jp} ; Fumiaki Isohashi¹ ; Hiroko Yamaguchi¹ ; Seiji Mabuchi² ; Ken Yoshida³ ; Tadayuki Kotsuma⁴ ; Hideya Yamazaki⁵ ; Eiichi Tanaka⁴ ; Iori Sumida¹ ; Keisuke Tamari¹ ; Keisuke Otani¹ ; Yuji Seo¹ ; Osamu Suzuki⁶ ; Yasuo Yoshioka¹ ; Tadashi Kimura² ; Kazuhiko Ogawa¹
• 关键词：Endometrial cancer ; Brachytherapy ; Vaginal recurrence ; High dose rate
• 刊名：Brachytherapy
• 出版年：2016
• 出版时间：November-December 2016
• 年：2016
• 卷：15
• 期：6
• 页码：812-816
• 全文大小：241 K
• 卷排序：15

文摘

We have retrospectively analyzed the outcomes of high-dose-rate (HDR) brachytherapy as a salvage therapy for vaginal recurrence of endometrial cancer.Methods and MaterialsFrom 1997 to 2012, salvage HDR brachytherapy was performed in 43 patients. The median age was 64 years (range, 41–88 years). HDR brachytherapy was performed by interstitial brachytherapy in 34 patients (79%) and by intracavity brachytherapy in nine patients (21%). Seventeen (40%) of the 43 patients were treated with external beam radiotherapy. The median followup period was 58 months (range, 6–179 months).ResultsThe 5-year overall survival (OS), progression-free survival (PFS), and local control rates (LC) were 84%, 52%, and 78%, respectively. Patients who received brachytherapy with external beam radiotherapy experienced no nodal recurrence (0 of 17 patients), whereas 23% of the patients (6 of 26 patients) who received brachytherapy alone experienced nodal recurrence (p = 0.047). The pathologic grade at the time of initial surgery (G1-2 vs. G3) was found to be a significant prognostic factor for both OS and PFS. The respective 5-year OS was 96% vs. 40% (p < 0.01), and the 5-year PFS was 58% vs. 0% (p < 0.01). Age (≥60 vs. <60) and modality (interstitial brachytherapy vs. intracavity brachytherapy) were significant prognostic factors for LC. The respective 5-year LC was 74% vs. 100% (p = 0.020) and 85% vs. 56% (p = 0.035).ConclusionsHDR brachytherapy is effective and feasible in patients with isolated vaginal recurrence of endometrial cancer. Pathologic grade, age, and modality were significant prognostic factors.